Payment overview · 2025
General Payments
$554.52
18 reported records · 6 companies
Healthcare provider profile · identity verified
Himanshu Pandya, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLORAL PARK, NY · NPI 1003896929
Verified facts
What the public records show
CMS Open Payments records show Himanshu Pandya, MD received $554.52 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.69 | 35.5% | 5 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $161.54 | 29.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $103.51 | 18.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.15 | 7.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.53 | 6.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.10 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.52 | 17 |
| Education | $5.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $162.18 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $161.54 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $126.05 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 215 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
215 | 47 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
215 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1090 | 285 |
| Amlodipine Besylate | Amlodipine Besylate | 823 | 204 |
| Levothyroxine Sodium | Levothyroxine Sodium | 765 | 176 |
| Losartan Potassium | Losartan Potassium | 757 | 181 |
| Metformin Hcl | Metformin Hcl | 615 | 152 |
| Eliquis | Apixaban | 597 | 64 |
| Simvastatin | Simvastatin | 429 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 419 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 412 | 148 |
| Gabapentin | Gabapentin | 400 | 106 |
| Furosemide | Furosemide | 383 | 81 |
| Famotidine | Famotidine | 374 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 321 | 68 |
| Januvia | Sitagliptin Phosphate | 305 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 304 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 294 | 72 |
| Azithromycin | Azithromycin | 258 | 207 |
| Meloxicam | Meloxicam | 249 | 136 |
| Lisinopril | Lisinopril | 226 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 57 |
| Jardiance | Empagliflozin | 215 | 47 |
| Omeprazole | Omeprazole | 211 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 62 |
| Montelukast Sodium | Montelukast Sodium | 176 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 172 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 169 | 54 |
| Metformin Hcl Er | Metformin Hcl | 163 | 54 |
| Hydrocortisone | Hydrocortisone | 156 | 74 |
| Carvedilol | Carvedilol | 152 | 42 |
| Mirtazapine | Mirtazapine | 150 | 26 |
| Allopurinol | Allopurinol | 146 | 34 |
| Glimepiride | Glimepiride | 138 | 35 |
| Donepezil Hcl | Donepezil Hcl | 132 | 29 |
| Divalproex Sodium | Divalproex Sodium | 129 | 16 |
| Finasteride | Finasteride | 128 | 24 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 125 | 56 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 125 | 52 |
| Atenolol | Atenolol | 116 | 24 |
| Prednisone | Prednisone | 114 | 47 |
| Ozempic | Semaglutide | 109 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 25 |
| Farxiga | Dapagliflozin Propanediol | 100 | 25 |
| Glipizide | Glipizide | 97 | 29 |
| Labetalol Hcl | Labetalol Hcl | 93 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 22 |
| Meclizine Hcl | Meclizine Hcl | 89 | 43 |
| Fenofibrate | Fenofibrate Nanocrystallized | 87 | 30 |
| Latanoprost | Latanoprost | 85 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 85 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 13 |
| Alendronate Sodium | Alendronate Sodium | 82 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 79 | 22 |
| Warfarin Sodium | Warfarin Sodium | 77 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 75 | 18 |
| Trazodone Hcl | Trazodone Hcl | 72 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 67 | 24 |
| Clobetasol Propionate | Clobetasol Propionate | 64 | 26 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 16 |
| Enalapril Maleate | Enalapril Maleate | 63 | 17 |
| Glipizide Er | Glipizide | 63 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 62 | 25 |
| Nifedipine Er | Nifedipine | 62 | 18 |
| Levetiracetam | Levetiracetam | 61 | 11 |
| Memantine Hcl | Memantine Hcl | 60 | 15 |
| Olanzapine | Olanzapine | 59 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 57 | 22 |
| Valsartan | Valsartan | 57 | 14 |
| Ammonium Lactate | Ammonium Lactate | 55 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 55 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | suppressed |
| Novolog Flexpen | Insulin Aspart | 54 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 15 |
| Tramadol Hcl | Tramadol Hcl | 53 | 14 |
| Ezetimibe | Ezetimibe | 52 | 15 |
| Cefuroxime | Cefuroxime Axetil | 51 | 47 |
| Clozapine | Clozapine | 51 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 16 |
| Repaglinide | Repaglinide | 51 | 14 |
| Potassium Chloride | Potassium Chloride | 49 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 48 | 19 |
| Brimonidine Tartrate | Brimonidine Tartrate | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 47 | 14 |
| Naproxen | Naproxen | 46 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 24 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Ramipril | Ramipril | 43 | 15 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Metolazone | Metolazone | 39 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 39 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 12 |
| Ketoconazole | Ketoconazole | 38 | 16 |
| Loperamide | Loperamide Hcl | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 28 |
| Lactulose | Lactulose | 33 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Methimazole | Methimazole | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Folic Acid | Folic Acid | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 22 |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 20 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Baclofen | Baclofen | 30 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | 15 |
| Nystatin | Nystatin | 30 | 16 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Calcipotriene-Betamethasone | Calcipotriene/Betamethasone | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | 11 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 13 |
| Rytary | Carbidopa/Levodopa | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Admelog Solostar | Insulin Lispro | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Nyamyc | Nystatin | 27 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 25 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 14 |
| Acetylcysteine | Acetylcysteine | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Restasis | Cyclosporine | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Alogliptin | Alogliptin Benzoate | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 21 | 12 |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Proctozone-Hc | Hydrocortisone | 21 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 20 | 13 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 18 | 17 |
| Digoxin | Digoxin | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Jentadueto | Linagliptin/Metformin Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Olanzapine Odt | Olanzapine | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Tivicay | Dolutegravir Sodium | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Bumetanide | Bumetanide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $554.52 · 18 records | AstraZeneca Pharmaceuticals LP | AREXVY, BREZTRI, FARXIGA, JARDIANCE, MOUNJARO, OTEZLA, REPATHA, SPRAVATO, TRELEGY ELLIPTA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error